Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Hiroshi, Takatani"'
Autor:
Mikio Oka, Minoru Fukuda, Takeshi Kitazaki, Seiji Nagashima, Kazuhiro Tsukamoto, Takashi Kasai, Takaya Ikeda, Hirofumi Nakano, Hiroshi Takatani, Katsumi Nakatomi, Hiroyuki Yamaguchi, Shigeru Kohno, Yoichi Nakamura
Publikováno v:
Chemotherapy. 61:93-98
Background: S-1, a novel oral fluoropyrimidine, is active in the treatment of non-small cell lung cancer (NSCLC). However, data on S-1 for elderly patients with NSCLC are insufficient. Methods: Eligibility criteria were no prior chemotherapy, stage I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56f519fffd810c30e01ca03e817ea466
https://doi.org/10.1159/000441486
https://doi.org/10.1159/000441486
Autor:
K. Kuroda, T. Fukuda, Masaaki Fukuda, Hiroko Hayashi, Shin Tsutsui, Y. Ogihara, M. Mori, Hiroshi Mukae, S. Yoshida, K Minami, K. Fukushima, Kazuto Ashizawa, Takeshi Nagayasu, A Fukushima, Hiroshi Takatani, Konosuke Morimoto, Hiroyuki Yamaguchi
Publikováno v:
Journal of Thoracic Oncology. 14:S811
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fee352aa2e1301e47bd5bea90a49ea82
https://doi.org/10.1016/j.jtho.2019.08.1743
https://doi.org/10.1016/j.jtho.2019.08.1743
Autor:
Norihito Kaku, Seiji Nagashima, Minoru Fukuda, Hiroshi Takatani, Masaaki Fukuda, Kohji Hashiguchi, Katsunori Yanagihara, Yoshitomo Morinaga, Koichi Izumikawa, Hiroshi Kakeya, Yoshihiro Yamamoto, Shigeru Kohno
Publikováno v:
Journal of Infection and Chemotherapy. 19(1):70-76
Healthcare-associated pneumonia (HCAP) is a new concept of pneumonia, which was proposed in the ATS/IDSA guidelines. The guidelines explain that HCAP patients should be treated with broad-spectrum antimicrobial drugs directed at multidrug-resistant p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2f5253e7d2f3f0e8ce7a88b6c2ecd3
http://hdl.handle.net/10069/31699
http://hdl.handle.net/10069/31699
Autor:
Hiroshi Takatani, Yoichi Nakamura, Hiroshi Soda, Kazuhiro Tsukamoto, Tetsuya Iida, Takashi Kasai, Masaaki Fukuda, Minoru Fukuda, Shigeru Kohno, Akitoshi Kinoshita, Seiji Nagashima, Yoshifumi Soejima, Mikio Oka, Katsumi Nakatomi
Publikováno v:
Clinical Lung Cancer. 13:347-351
The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced Non-Small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c08f52511ac060d21d793c04334924
https://doi.org/10.1016/j.cllc.2011.11.007
https://doi.org/10.1016/j.cllc.2011.11.007
Autor:
Minoru Fukuda, Nanae Tomonaga, Mineyo Takasu, Hirofumi Nakano, Hiroyuki Yamaguchi, Seiji Nagashima, Shigeru Kohno, Yoichi Nakamura, Hiroshi Soda, Seiji Doi, Tomayoshi Hayashi, Kazuhiro Tsukamoto, Hiroshi Takatani, Katsumi Nakatomi
Publikováno v:
Cancer chemotherapy and pharmacology. 67(2):331-338
PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1fa1ee3695e2c05cca2d54b4b7ef28e
https://nagasaki-u.repo.nii.ac.jp/records/15296
https://nagasaki-u.repo.nii.ac.jp/records/15296
Autor:
Yoshifumi Soejima, Hiroshi Takatani, Kazuhiro Tsukamoto, Akitoshi Kinoshita, Katsumi Nakatomi, Seiji Nagashima, Takashi Kasai, Mikio Oka, Noriyuki Masuda, Masaaki Fukuda, Minoru Fukuda, Shigeru Kohno, Hiroshi Soda, Yoichi Nakamura
Publikováno v:
Journal of Thoracic Oncology : official publication of the International Association for the Study of Lung Cancer. 6(1):121-127
Irinotecan-containing regimens are known to be active and tolerable in patients with non-small cell lung cancer (NSCLC). A randomized phase II trial was conducted to evaluate the efficacy of irinotecan plus paclitaxel or gemcitabine for previously un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca3245431033fbf72349ea3e054155e
https://nagasaki-u.repo.nii.ac.jp/records/14758
https://nagasaki-u.repo.nii.ac.jp/records/14758
Autor:
Minoru Fukuda, Hiroshi Takatani, Kazuhiro Tsukamoto, Shigeru Kohno, Seiji Nagashima, Yoichi Nakamura, Hiroshi Soda, Kazumi Sano, Mikio Oka, Tomayoshi Hayashi
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 5(9):1404-1409
INTRODUCTION: We assessed the relationship between the plasma concentration of gefitinib and its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC). METHODS: Plasma trough levels of gefitinib were measured on days 3 (D3) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff42abbc21d2d0d95e7303c68a177b5
https://nagasaki-u.repo.nii.ac.jp/records/14189
https://nagasaki-u.repo.nii.ac.jp/records/14189
Autor:
Seiji Nagashima, Shigeru Kohno, Katsumi Nakatomi, Akitoshi Kinoshita, Hiroshi Soda, Seiji Doi, Hiroshi Takatani, Mikio Oka, Takashi Kasai, Yoichi Nakamura, Kazuhiro Tsukamoto, Minoru Fukuda, Masaaki Fukuda, Hirofumi Nakano
Publikováno v:
Journal of Thoracic Oncology. 4(6):741-745
BackgroundAmrubicin and cisplatin are active in the treatment of small cell lung cancer (SCLC), and carboplatin is an analogue of cisplatin with less nonhematological toxicity. The appropriate dose of amrubicin and carboplatin combination chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae78c8acc41b96622375411d56ab4cba
Autor:
Yoichi Hirakata, Katsunori Yanagihara, Kazunori Minami, Yasuhito Higashiyama, Norihiro Kohara, Yoshitsugu Miyazaki, Shigeru Kohno, Yuji Ishimatsu, Keiji Inoue, Yasumasa Dohtsu, Hiroshi Takatani
Publikováno v:
Journal of the Japanese Association for Infectious Diseases. 79:656-663
Clinical studies of sixteen cases with pulmonary cryptococcosis, during the past six years between 1998 and 2004, were peformed mainly with respect to serum cryptococcal antigen titer. Serum cryptococcal antigen was positive in twelve of 16 cases, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::557b26063bdb523e69cce9e83961ccd5
https://doi.org/10.11150/kansenshogakuzasshi1970.79.656
https://doi.org/10.11150/kansenshogakuzasshi1970.79.656
Autor:
Yoshifumi Soejima, Minoru Fukuda, Shigeru Kohno, Hiroshi Soda, Mutsuo Kuba, Junji Tsurutani, Akitoshi Kinoshita, Mikio Oka, Seiji Nagashima, Yoichi Nakamura, Takashi Kasai, Masaaki Fukuda, Hiroshi Takatani, Yuichi Inoue
Publikováno v:
Cancer Chemotherapy and Pharmacology. 54:573-577
Irinotecan, a topoisomerase I inhibitor, is an effective agent for non-small-cell lung cancer (NSCLC). To determine the efficacy and toxicity of irinotecan and carboplatin, we conducted a phase II study in 61 patients with advanced NSCLC. Every 4 wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::453cba4e80aabf443ec885da2f62efc0
https://doi.org/10.1007/s00280-004-0805-2
https://doi.org/10.1007/s00280-004-0805-2